Angiotensin receptor blockers: impact on costs of care

Area of Science:

• Cardiovascular Medicine
• Pharmacoeconomics
• Nephrology

Background:

• Hypertension treatment incurs substantial annual costs, estimated at nearly $60 billion.
• Healthcare utilization and treatment expenses are critical factors in selecting antihypertensive therapies.
• Previous studies highlight the economic impact of managing hypertension and its comorbidities.

Purpose of the Study:

• To evaluate the cost-effectiveness of angiotensin receptor blockers (ARBs) in hypertension management.
• To assess the impact of ARBs on healthcare utilization and clinical outcomes.
• To determine the economic benefits of ARBs in specific patient populations.

Main Methods:

• Review of existing studies on ARB treatment in hypertensive patients.
• Analysis of healthcare costs associated with ARB therapy versus other treatments.
• Examination of clinical end points, including end-stage renal disease, survival rates, and hospital admissions.

Main Results:

• ARBs significantly reduce healthcare costs in patients with hypertension and type 2 diabetes.
• Treatment with ARBs leads to a decreased incidence of end-stage renal disease and improved survival.
• Cost savings are also observed in heart failure patients due to reduced healthcare visits and hospitalizations.

Conclusions:

• Angiotensin receptor blockers represent a cost-effective therapeutic option for hypertension.
• ARBs provide significant economic benefits by mitigating severe clinical outcomes and reducing healthcare resource utilization.
• The use of ARBs should be strongly considered in the management of hypertension, especially in patients with diabetes and heart failure.